If you find our technology combined with your drug commercially interesting, the next steps could be to:

• sign a confidentiality agreement
• send you our confidential technology prospect
• start a 3 – 6 months feasibility study
• start a full-scale product development project

Use the following contact information or contact form:

Harry Jalonen, CEO
DelSiTech Ltd
Itäinen Pitkäkatu 4 B
20520 Turku
Finland

Phone: +358 2 4788 642
Mobile: +358 50 336 7972
Fax: +358 2 4788 120